Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cosyntropin (Cortrosyn) vs Icatibant (Firazyr)
An educational, source-based comparison of Cosyntropin (Cortrosyn) and Icatibant (Firazyr) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic peptide containing the first 24 amino acids of ACTH — retains full corticotropic activity. Stimulates adrenal cortisol release for diagnostic testing.
- Primary and secondary adrenal insufficiency diagnosis
- • FDA-approved.
- • Single diagnostic dose; very well tolerated.
Bradykinin B2 receptor antagonist for hereditary angioedema attacks.
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.
- Hereditary angioedema (acute attacks)
- • FDA-approved.
- • Injection-site reactions very common.
Cosyntropin (Cortrosyn) vs Icatibant (Firazyr) — Key differences
- Class: Cosyntropin (Cortrosyn) is classified as Diagnostic · Endocrine, while Icatibant (Firazyr) is Bradykinin Antagonist · Immunology.
- Primary research focus: Cosyntropin (Cortrosyn) — primary and secondary adrenal insufficiency diagnosis; Icatibant (Firazyr) — hereditary angioedema (acute attacks).
- Tag: FDA-Approved · Diagnostic vs FDA-Approved · Rare Disease.